Alphabet’s Verily scores FDA clearance for its ECG monitor

Big week for Google wearable report — which, honestly, is not a phrase I expected to write in 2019. But a day after the company announced an agreement to purchase Fossil’s wearable technology for $40 million, Alphabet-owned research group Verily just scored FDA clearance for its electrocardiogram( ECG) engineering.

The clearance pertains specifically to the company’s Study Watch. The machine, which was announced back in 2017, shouldn’t be confused with the company’s more consumer-facing Wear OS attempts. Instead, the product is designed expressly for the purposes of applying amas vitals for serious medical studies of conditions like MS and Parkinson’s.

“The ability to take an on-demand, single-lead ECG, can support both population-based research and an individual’s clinical care, ” Verily writes on its blog. “Receiving this clearance showcases our commitment to the a high level of the FDA for safety and effectiveness and will help us improvement the implementation of Study Watch in various cancer the regions and future indications.”

The Study Watch is a prescription-only machine, but the clearance leaves one wondering how this might open the door for the purposes of an upcoming Pixel Watch. After all, Fossil’s recently released Wear OS machines had a chose health focus, in keeping with most recent smartwatches. After Apple’s recent addition of ECG on the Series 4 Watch, it tracks that Google would want to go to sell with a similar health-focused aspect set.

Meantime, this news should open the door for the E Ink device’s ability to help collect some meaningful info for medical researchers.

Read more: feedproxy.google.com